Jump to content

GSK and Vaccine research


Recommended Posts

LONDON, June 5 (Reuters) - GlaxoSmithKline Plc (GSK.L: Quote, Profile, Research) has signed a deal to license in a substantial portfolio of tumour-specific antigens from the international Ludwig Institute for Cancer Research to boost its cancer vaccine portfolio.

Financial terms of the deal, announced on Monday, were not disclosed.

Tumour-specific antigens are proteins expressed only by tumour cells and, when given in combination with special vaccine adjuvants, they are expected to trigger a specific immune response to eliminate cancer cells.

The move to expand access to the institute's antigens follows news at the weekend that an experimental Glaxo vaccine showed promise in a mid-stage trial for preventing a recurrence of lung cancer [iD].

© Reuters 2006. All Rights Reserved.

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.